Overview

Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Examination of the correlation between the cerebral bloodflow and the clinical change under treatment with Reminyl retard® and the prediction of clinical change by measuring the cerebral bloodflow in patients with mild to moderate Alzheimer's Disease

Phase:

N/A

Details

Lead Sponsor:

University Hospital, Bonn

Collaborator:

Federal Ministry of Health, Germany

Treatments:

Galantamine